8-K: Illumina to Acquire SomaLogic, Bolstering Proteomics and Multiomics Strategy for $350 Million Cash Plus Milestones

Illumina, Inc. has announced a definitive agreement to acquire SomaLogic's aptamer-based and functional proteomics business from Standard BioTools Inc. for $350 million in cash, with potential additional milestone payments and royalties, aiming to accelerate its multiomics strategy and expand its presence in the proteomics market.

Summary

• Illumina, Inc. (ILMN) will acquire SomaLogic, Inc. and other related entities (Sengenics Corporation LLC, Sengenics Corporation Pte Ltd) from Standard BioTools Inc. (LAB).
• The acquisition includes SomaLogic's aptamer-based and functional proteomics business, specifically KREX, Single SOMAmer, translational, and diagnostic assays, but excludes Standard BioTools' mass cytometry and microfluidics businesses.
• The purchase price is $350,000,000 in cash at closing, subject to customary adjustments, along with potential milestone payments of up to $75,000,000 and royalty streams based on future revenues from certain products and services.
• The transaction is expected to close in the first half of 2026, pending customary closing conditions, including required regulatory clearances under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
• Illumina and Standard BioTools will enter into several ancillary agreements, including a transition services agreement and a license agreement for certain intellectual property.
• The acquired business is projected to become profitable on a non-GAAP operating income basis in 2027, with non-GAAP operating margins aligning with Illumina's in 2028.
• SomaLogic has approximately 250 employees globally across commercial, R&D, lab operations, and manufacturing, and its Boulder, Colorado facilities (including a CLIAand CAP-certified lab) are part of the acquisition.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment regarding the strategic benefits and future financial prospects of the acquisition. It highlights market expansion, technological acceleration, and expected profitability, with risks being standard for such transactions and well-articulated as forward-looking statements.

Positives

• The acquisition enhances Illumina's presence in the expanding proteomics market, aligning with and advancing its multiomics strategy.
• It is expected to strengthen the value of Illumina's NovaSeq X product and unlock greater capabilities for advanced biomarker discovery and disease profiling.
• Combining SomaLogic's technology with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics is anticipated to accelerate the technology development roadmap for proteomics and reduce research time and cost.
• The kitted NGS-based panels business from SomaLogic is expected to add a high-margin consumables revenue stream.
• The acquired business is projected to achieve profitability on a non-GAAP operating income basis by 2027, with non-GAAP operating margins in line with Illumina's by 2028.

Negatives

• The acquisition is subject to customary adjustments at closing, which could slightly alter the final cash payment.
• The realization of up to $75,000,000 in milestone payments and royalty streams is contingent on future performance and revenues, introducing an element of uncertainty.
• The integration of SomaLogic into Illumina's existing operations and portfolio presents a challenge that could impact the anticipated benefits.
• There are inherent challenges in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components.

Risks

• Failure to consummate the proposed transaction on the anticipated terms and timeline, including the ability of the parties to obtain required regulatory approvals (e.g., Hart-Scott-Rodino Act in the United States or from government authorities outside the United States) and to satisfy other closing conditions.
• Uncertainty regarding the future conduct and growth of the business and the markets in which Illumina operates, including the proteomics market.
• The success of products and services competitive with Illumina's offerings.
• Challenges in successfully integrating SomaLogic into Illumina's existing operations and SomaLogic's technology and products into Illumina's portfolio.
• Risks related to Illumina's ability to sell SomaLogic's products and further develop SomaLogic's technology.
• Challenges in successfully managing partner and customer relationships in the proteomics market.
• Risks associated with Illumina's ability to manufacture robust instrumentation and consumables, including SomaLogic's products.
• Inherent challenges in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components.
• Uncertainty regarding customer uptake of, and satisfaction with, new products and services.
• Potential for business disruption, operational problems, financial loss, or legal liability to third parties if actual results differ materially from forward-looking statements.

Future Outlook

Illumina expects the acquisition to enhance its presence in the expanding proteomics market and advance its multiomics strategy. The acquired business is projected to become profitable on a non-GAAP operating income basis in 2027, with non-GAAP operating margins aligning with Illumina's in 2028. Illumina Protein Prep is expected to be available to all customers starting in the third quarter of 2025. The company intends to maintain and support existing proteomics partnerships and continue developing its sequencing ecosystem and multiomics solutions.

Management Comments

• Jacob Thaysen, CEO of Illumina: "This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future."
• Jacob Thaysen, CEO of Illumina: "Illumina and SomaLogic have partnered closely for more than three years, and this combination increases our ability to serve our customers and accelerate our technology roadmap towards advanced biomarker discovery and disease profiling."
• Jacob Thaysen, CEO of Illumina: "We are taking the scalability of NGS into proteomics."
• Jacob Thaysen, CEO of Illumina: "Illumina will remain an open, accessible, and enabling NGS platform. The Company is committed to maintaining and supporting its existing proteomics partnerships as well as continuing to develop the sequencing ecosystem and supporting a wide variety of multiomics solutions."

Industry Context

This acquisition positions Illumina to expand its leadership in the rapidly growing proteomics market, complementing its existing strength in genomics and advancing its broader multiomics strategy. By integrating SomaLogic's aptamer-based proteomics technology, Illumina aims to offer more comprehensive solutions for biomarker discovery and disease profiling, leveraging its high-throughput next-generation sequencing (NGS) platforms. This move reflects a broader industry trend towards integrating different 'omics' technologies (genomics, proteomics, metabolomics) to provide a more holistic understanding of biological systems, which is crucial for precision medicine and drug development.

Comparison to Industry Standards

• The acquisition of SomaLogic's aptamer-based proteomics platform enhances Illumina's competitive standing against other companies in the proteomics space, such as Olink (acquired by Thermo Fisher Scientific) and Seer, Inc., by integrating a complementary technology directly into its NGS ecosystem.
• Illumina's existing co-development agreement with SomaLogic since December 2021, which brought the SomaScan Proteomics Assay onto Illumina's NGS platforms, indicates a pre-existing strategic alignment and technical compatibility, potentially leading to a smoother integration compared to entirely new partnerships.
• The stated goal of achieving profitability for the acquired business by 2027 and aligning operating margins with Illumina's by 2028 suggests a strategic financial target for the integration, aiming for long-term value creation within the competitive life sciences tools sector.

Management Changes

Corporate Governance

Legal Proceedings

• There are no pending or threatened material legal proceedings against any Group Company, any Company Associate (in their capacity as such), or any assets owned or used by any Group Company or relating to the Business.
• No person has threatened in writing to commence any legal proceedings that would reasonably be expected to prevent, materially impair, or materially delay the consummation of the Transactions.
• No Group Company or Seller Group member is subject to any outstanding Order that would reasonably be expected to be material to the Group Companies or the Business.
• No material investigation of any Group Company or the Business by any Governmental Authority is pending or threatened.

Related Party Transactions

• No officer, director, manager, or Affiliate of a member of the Seller Group or of a Group Company (other than another Group Company), or any individual in such officer's, director's, or manager's immediate family, is a party to any Contract with any Group Company or related to the Business (excluding employment-related Contracts, Company Plans, and confidentiality Contracts or other Contracts incident to such Person's employment with a Group Company).
• No such related party has any ownership of any material property used in or necessary for the conduct of the Business.

Stakeholder Impact

• **Shareholders (Illumina):** Expected to benefit from expanded market presence in proteomics, acceleration of multiomics strategy, and potential for high-margin revenue streams and future profitability from the acquired business.
• **Shareholders (Standard BioTools):** Will receive $350 million in cash at closing, plus potential milestone payments and royalties, providing a significant cash infusion and future revenue streams from the divestiture.
• **Employees (SomaLogic):** Approximately 250 employees will transition to Illumina, with provisions for continued base salary, target cash incentive opportunities, severance benefits, and other employee benefits comparable to pre-closing or similarly situated Illumina employees. Service credit for prior employment will be recognized for eligibility and vesting purposes.
• **Customers:** Existing proteomics partnerships will be maintained and supported. Customers are expected to benefit from accelerated technology development, reduced research time and cost, and the broader availability of Illumina Protein Prep starting in Q3 2025.
• **Suppliers:** Illumina commits to preserving business relationships with manufacturers, suppliers, and vendors of the acquired business.

Next Steps

• Illumina and Standard BioTools will make necessary filings under the Hart-Scott-Rodino Act in the United States.
• The parties will work to obtain required regulatory clearances and satisfy other customary closing conditions.
• Illumina Protein Prep will become available to all customers starting in the third quarter of 2025.
• Illumina will work towards integrating SomaLogic into its existing operations and portfolio.
• Illumina will continue to develop the sequencing ecosystem and support a wide variety of multiomics solutions.
• Standard BioTools will implement Key Business Employee Retention Programs to incentivize certain key Business Employees to remain employed throughout the pre-closing period.
• Standard BioTools will transfer Business Employees to a Group Company and transfer non-Business Employees from Group Companies to the Seller Group prior to closing.
• Standard BioTools will transfer sponsorship of certain Company Plans to a member of the Seller Group and others to a Group Company (Assumed Plan) prior to closing.
• Illumina will make offers of employment to Business Employees in specific jurisdictions at least 5 business days prior to closing.

Key Dates

Recommendation

Keywords

Illumina, SomaLogic, Standard BioTools, Acquisition, Proteomics, Multiomics, Next-Generation Sequencing, NGS, Biomarker Discovery, Disease Profiling, Life Sciences, Biotechnology, Merger, Healthcare Technology, Consumables, KREX, Single SOMAmer, Translational Assays, Diagnostic Assays, Regulatory Approval, Hart-Scott-Rodino Act